Uma N Rao
Overview
Explore the profile of Uma N Rao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McLouth L, Zheng Y, Smith S, Hodi F, Rao U, Cohen G, et al.
Qual Life Res
. 2022 Aug;
32(1):183-196.
PMID: 36029412
Purpose: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related...
2.
Vaz J, Tian C, Richardson M, Chan J, Mysona D, Rao U, et al.
Gynecol Oncol
. 2020 Jan;
157(1):121-130.
PMID: 31954536
Objectives: Determine the impact of adjuvant chemotherapy (ACT) and prognostic factors in surgically managed patients with stage I uterine leiomyosarcoma (ULMS). Methods: Women who underwent hysterectomy and were diagnosed with...
3.
Tahata S, Singh S, Lin Y, Hahm E, Beumer J, Christner S, et al.
Cancer Prev Res (Phila)
. 2018 Apr;
11(7):429-438.
PMID: 29691233
Broccoli sprout extract containing sulforaphane (BSE-SFN) has been shown to inhibit ultraviolet radiation-induced damage and tumor progression in skin. This study evaluated the toxicity and potential effects of oral BSE-SFN...
4.
Agarwala S, Lee S, Yip W, Rao U, Tarhini A, Cohen G, et al.
J Clin Oncol
. 2017 Jan;
35(8):885-892.
PMID: 28135150
Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) in...
5.
Paraiso K, Das Thakur M, Fang B, Koomen J, Fedorenko I, John J, et al.
Cancer Discov
. 2014 Dec;
5(3):264-73.
PMID: 25542447
Unlabelled: Many patients with BRAF inhibitor resistance can develop disease at new sites, suggesting that drug-induced selection pressure drives metastasis. Here, we used mass spectrometry-based phosphoproteomic screening to uncover ligand-independent...
6.
Hodi F, Lee S, Mcdermott D, Rao U, Butterfield L, Tarhini A, et al.
JAMA
. 2014 Nov;
312(17):1744-53.
PMID: 25369488
Importance: Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in...
7.
Raab S, Grzybicki D, Mahood L, Parwani A, Kuan S, Rao U
Am J Clin Pathol
. 2008 Nov;
130(6):905-12.
PMID: 19019767
Different error detection methods yield different error proportions and have variable benefits for surgical pathology divisions with limited resources. We performed a nonconcurrent cohort study at a large institution that...
8.
Ren B, Yu Y, Tseng G, Wu C, Chen K, Rao U, et al.
J Natl Cancer Inst
. 2007 Jun;
99(11):868-80.
PMID: 17551147
Background: Integrins are the major adhesive molecules in mammalian cells. Each integrin subtype plays a unique role in cell differentiation and embryo development. However, integrin involvement in carcinogenesis has not...
9.
Moschos S, Edington H, Land S, Rao U, Jukic D, Shipe-Spotloe J, et al.
J Clin Oncol
. 2006 Jul;
24(19):3164-71.
PMID: 16809739
Purpose: Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overall survival in patients with high-risk melanoma. However, its mechanism of action is largely unknown. Therefore, HDI was investigated in the neoadjuvant...